Compare ETON & TCPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ETON | TCPC |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 498.8M | 517.5M |
| IPO Year | 2018 | 2012 |
| Metric | ETON | TCPC |
|---|---|---|
| Price | $16.71 | $6.08 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 3 | 2 |
| Target Price | ★ $29.67 | $6.50 |
| AVG Volume (30 Days) | 277.8K | ★ 576.3K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 20.10% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $70,316,000.00 | ★ $219,119,058.00 |
| Revenue This Year | $113.27 | N/A |
| Revenue Next Year | $36.70 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 102.77 | N/A |
| 52 Week Low | $11.09 | $5.39 |
| 52 Week High | $23.00 | $9.72 |
| Indicator | ETON | TCPC |
|---|---|---|
| Relative Strength Index (RSI) | 49.52 | 57.31 |
| Support Level | $16.13 | $6.07 |
| Resistance Level | $17.05 | $6.25 |
| Average True Range (ATR) | 0.76 | 0.12 |
| MACD | 0.16 | 0.02 |
| Stochastic Oscillator | 79.06 | 68.97 |
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights or direct equity investments.